EMA advises on intradermal use of Imvanex/Jynneos against monkeypox

The European Medicines Agency’s (EMA) Emergency Task Force (EFT) has reviewed data on the monkeypox vaccine Imvanex used as an intradermal injection.

The vaccine was developed by Denmark’s Bavarian Nordic’s (OMX: BAVA), which also markets it under the Jynneos trade name in the USA.

The vaccine is only authorized for subcutaneous injection (injection under the skin). However, when given intradermally, a smaller dose of the vaccine can be used. Given the currently limited supply of the vaccine, this means that more people can be vaccinated, the EMA noted.